Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346080 | 0.95 | PDE4B (0.43) | PDE4BCCNT1MAPK1TP53 | |
| SCHEMBL4360896 | 0.94 | PDE4B (0.40) | PDE4BCCNT1MAPK1TP53 | |
| SCHEMBL4349724 | 0.94 | PDE4B (0.40) | PDE4BCCNT1MAPK1TP53 | |
| SCHEMBL3427091 | 0.94 | PDE4B (0.39) | PDE4BCCNT1MAPK1 | |
| SCHEMBL4106607 | 0.93 | PDE4B (0.42) | PDE4BRIPK2POLBTP53 | |
| SCHEMBL4359945 | 0.93 | PDE4B (0.41) | PDE4BRIPK2CCNT1MAPK1TP53 | |
| SCHEMBL4355984 | 0.91 | PDE4B (0.43) | PDE4BMAPK1 | |
| SCHEMBL13750944 | 0.89 | PDE4B (0.43) | PDE4BMAPK1 | |
| SCHEMBL4100618 | 0.87 | PDE4B (0.42) | PDE4BCCNT1MAPK1TP53 | |
| SCHEMBL3431327 | 0.87 | PDE4B (0.42) | PDE4BCCNT1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | PDE4B 2/4885RIPK2 3428/4885CCNT1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.